Suppression by pravastatin, an inhibitor of p21 ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats
1998

Pravastatin Reduces Liver Cancer in Rats

Sample size: 60 publication Evidence: moderate

Author Information

Author(s): M Tatsuta, H Iishi, M Babal, K Iseki, H Yanol, H Uehara, R Yamamoto, A Nakaizumi

Primary Institution: Osaka Medical Center for Cancer and Cardiovascular Diseases

Hypothesis

Does pravastatin inhibit hepatocarcinogenesis induced by N-nitrosomorpholine in rats?

Conclusion

Pravastatin significantly suppresses the development of liver cancer in rats exposed to a carcinogen.

Supporting Evidence

  • Pravastatin reduced the incidence, number, and volume of visible white nodules in treated rats.
  • Histological analysis showed significant reductions in hepatic lesions in pravastatin-treated groups.
  • Pravastatin increased apoptotic indices in neoplastic nodules.

Takeaway

Pravastatin helps prevent liver cancer in rats by stopping cancer cells from growing.

Methodology

Sixty male Sprague-Dawley rats were divided into three groups, with two groups receiving pravastatin and one group as a control, and were monitored for liver lesions after exposure to a carcinogen.

Limitations

The study was conducted on rats, and results may not directly translate to humans.

Participant Demographics

Young male Sprague-Dawley rats, 6 weeks old.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication